Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) and Caribou Biosciences (NASDAQ:CRBU – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.
Risk & Volatility
Tenaya Therapeutics has a beta of 2.72, meaning that its stock price is 172% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Tenaya Therapeutics and Caribou Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tenaya Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
| Caribou Biosciences | 0 | 0 | 4 | 0 | 3.00 |
Earnings & Valuation
This table compares Tenaya Therapeutics and Caribou Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tenaya Therapeutics | N/A | N/A | -$124.08 million | ($1.44) | -1.16 |
| Caribou Biosciences | $11.48 million | 14.20 | -$102.07 million | ($1.65) | -1.09 |
Caribou Biosciences has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 32.8% of Tenaya Therapeutics shares are held by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Tenaya Therapeutics and Caribou Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tenaya Therapeutics | N/A | -86.17% | -71.14% |
| Caribou Biosciences | -1,290.81% | -45.46% | -38.07% |
Summary
Tenaya Therapeutics beats Caribou Biosciences on 7 of the 12 factors compared between the two stocks.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
